drugset
drugset / Trial / NCT04855565

ALY688-SR in Generally Healthy Overweight or Obese Adults

NCT04855565 ↗

Phase 1 Terminated 8 enrolled Allysta Pharmaceutical INC Research Australia Pty Ltd · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

First in human study of ALY688-SR administered as a subcutaneous injection

Timeline

Start
2021-05-19
Primary completion
2021-08-03
Completion
2021-08-03

Outcome

Outcome not reported

Stopped (Enrollment): “Inability to recruit due to COVID-19 pandemic restrictions”

Drugs

EvaluationDrugModalityDoseRoute
Comparator ALY688-SR Unknown — Subcutaneous

Indications

No indication recorded.